{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:52:13Z","timestamp":1792093933362,"version":"4.4.0"},"reference-count":48,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Both prolactin excess and autoimmune (Hashimoto) thyroiditis may predispose to the development of cardiometabolic disorders. The aim of this study was to investigate whether autoimmune thyroiditis determines cardiometabolic effects of cabergoline. The study population consisted of 2 groups of young women: 32 women with euthyroid Hashimoto thyroiditis (group A) and 32 individuals without thyroid disorders (group B). Both groups were matched for age, body mass index, blood pressure, and prolactin levels. Plasma prolactin, thyroid antibodies, glucose homeostasis markers, plasma lipids, circulating levels of uric acid, high\u2010sensitivity C\u2010reactive protein (hsCRP), fibrinogen and homocysteine, and the urinary albumin\u2010to\u2010creatinine ratio were assessed before and after 6\u00a0months of cabergoline treatment.\u00a0All women completed the study. Both groups differed in thyroid antibody titers, insulin sensitivity, high\u2010density lipoprotein cholesterol, hsCRP, homocysteine, and the albumin\u2010to\u2010creatinine ratio. Although cabergoline treatment reduced prolactin levels, improved insulin sensitivity, decreased glycated hemoglobin, increased high\u2010density lipoprotein cholesterol, decreased hsCRP, and reduced the albumin\u2010to\u2010creatinine ratio in both treatment groups, these effects (except for glycated hemoglobin) were more pronounced in group B than in group A. Only in group B, the drug decreased triglycerides, uric acid, fibrinogen, and homocysteine. In group A, hsCRP levels correlated with both baseline thyroid antibody titers and with other cardiometabolic risk factors. The impact of cabergoline on cardiometabolic risk factors depended on the degree of reduction in prolactin levels, while in group A additionally correlated with the effect of treatment on hsCRP. The obtained results suggest that coexisting autoimmune thyroiditis attenuates cardiometabolic effects of cabergoline in young women with hyperprolactinemia.<\/jats:p>","DOI":"10.1002\/jcph.2245","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T10:35:06Z","timestamp":1681295706000},"page":"886-894","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Autoimmune Thyroiditis Attenuates Cardiometabolic Effects of Cabergoline in Young Women With Hyperprolactinemia"],"prefix":"10.1002","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5454-2620","authenticated-orcid":false,"given":"Robert","family":"Krysiak","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Clinical Pharmacology Medical University of Silesia  Katowice Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Kowalcze","sequence":"additional","affiliation":[{"name":"Department of Pediatrics in Bytom School of Health Sciences in Katowice Medical University of Silesia  Katowice Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogus\u0142aw","family":"Okopie\u0144","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Pharmacology Medical University of Silesia  Katowice Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8122203"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1159\/000499694"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2015.01.024"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1490187"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345182"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1015520"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2018.1434412"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020\u2010022\u201003238\u2010x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000357810"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000499470"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12307"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.vh.2017.07.001"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.007"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000500"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2986"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2008.0326"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02531.x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1178-5882"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2261-10-22"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000529242"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-198601000-00007"},{"key":"e_1_2_9_23_1","volume-title":"Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Effect Reporting to IRBs \u2013 Improving Human Subject Protection. Washington","author":"Food and Drug Administration","year":"2009"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.6.1487"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/10408363.2020.1723487"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00073"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2016.174"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1692"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-015-0346-z"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2016.09.013"},{"key":"e_1_2_9_31_1","first-page":"225","article-title":"Immunoanalytical characteristics of C\u2010reactive protein and high sensitivity C\u2010reactive protein","volume":"75","author":"Moutachakkir M","year":"2017","journal-title":"Ann Biol Clin (Paris)"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1480383"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom8030080"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.12.013"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2014.10.016"},{"key":"e_1_2_9_36_1","first-page":"51","article-title":"A concise review of Hashimoto thyroiditis (HT) and the importance of iodine, selenium, vitamin D and gluten on the autoimmunity and dietary management of HT patients. Points that need more investigation","volume":"20","author":"Liontiris MI","year":"2017","journal-title":"Hell J Nucl Med"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/2549491"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00327"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2007.03.006"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101241"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006865715292"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2006-0692"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-015-2490-5"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0064"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cnr.2006.04.002"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-08-0611"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2014.10.007"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345662"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.2307\/2533096"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.2245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T08:28:25Z","timestamp":1692347305000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.2245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,8]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1002\/jcph.2245"],"URL":"https:\/\/doi.org\/10.1002\/jcph.2245","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,8]]},"assertion":[{"value":"2023-02-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}